Autoimmune Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034

Autoimmune Diseases Diagnostics Market Summary

Overview:

• The Autoimmune Diseases Diagnostics market is estimated at USD 4.9 billion in 2025 and is projected to reach USD 8.0 billion by 2034. Growth is anchored in the rising global prevalence of autoimmune diseases, growing awareness and early diagnosis, and continuous advances in autoantibody testing, automation, and multiplex immunoassay technologies.
• The global Autoimmune Diseases Diagnostics market is growing at a CAGR of 5.53% during the forecast period from 2026 to 2034.
• By product, the reagents and kits segment dominated the Autoimmune Diseases Diagnostics market with a 68% share in 2025.
• By test type, the antinuclear antibody test segment dominated the Autoimmune Diseases Diagnostics market with a share of 32% in 2025.
• By technology, the immunofluorescence assay segment dominated the Autoimmune Diseases Diagnostics market with a share of 38% in 2025.
• By disease type, the systemic autoimmune disease segment dominated the Autoimmune Diseases Diagnostics market with a share of 62% in 2025.
• By end-user, the hospitals and clinics segment dominated the Autoimmune Diseases Diagnostics market with a share of 47% in 2025.
• North America dominated the global Autoimmune Diseases Diagnostics market revenue with a share of 42% in 2025, representing the highest regional market share globally.

Autoimmune diseases diagnostics comprises the tests, reagents, kits, and instruments used to detect, diagnose, and monitor autoimmune disorders, in which the immune system attacks the body's own tissues. The category spans autoantibody and antinuclear antibody testing, together with supporting tests such as complete blood count, comprehensive metabolic panel, C-reactive protein, erythrocyte sedimentation rate, and urinalysis, delivered through reagents and kits and the instruments that run them. Testing is performed using immunofluorescence assays, enzyme-linked immunosorbent assays, chemiluminescence immunoassays, and multiplex and line immunoassays, supplied by companies such as Thermo Fisher Scientific through its Phadia and EliA lines, Werfen through Inova Diagnostics, Bio-Rad Laboratories through BioPlex, Danaher through Beckman Coulter, Siemens Healthineers, Roche, Abbott, and Revvity through EUROIMMUN. Autoimmune diagnostics is used across systemic autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis, and localized autoimmune diseases affecting specific organs, in hospitals and clinics, diagnostic and reference laboratories, and other settings. Over the past decade, the field has advanced from manual immunofluorescence toward automated pattern recognition, high-throughput chemiluminescence, and multiplex platforms that measure many autoantibodies simultaneously, improving throughput, standardization, and early detection. Driven by the rising prevalence of autoimmune disease, growing awareness and earlier diagnosis, and continuous technological innovation, autoimmune disease diagnostics has become an important and growing segment of the in vitro diagnostics market.

Autoimmune Diseases Diagnostics Market Key Growth Drivers

• The rising global prevalence of autoimmune diseases, which collectively affect a large and growing share of the population, is expanding demand for autoimmune diagnostic testing.
• Growing awareness of autoimmune diseases among patients and clinicians, together with an emphasis on earlier and more accurate diagnosis, is increasing testing volumes.
• Continuous technological advances, including automated immunofluorescence, high-throughput chemiluminescence, and multiplex immunoassays, are improving throughput, standardization, and diagnostic capability.
• The expansion of autoantibody biomarker discovery and the growing menu of specific autoantibody tests are broadening the diagnostic and monitoring applications of autoimmune testing.
• The growing use of diagnostics to guide biologic and targeted therapy for autoimmune disease is increasing demand for testing and monitoring.
• Expanding healthcare access, laboratory capacity, and diagnostic awareness in emerging markets are broadening the global demand for autoimmune diagnostics.
• The convergence of rising autoimmune disease prevalence, earlier diagnosis, and advancing testing technology is expected to sustain steady growth in the global Autoimmune Diseases Diagnostics market through 2034.

Key Companies in Autoimmune Diseases Diagnostics Market

The competitive landscape is led by the following active developers and manufacturers of autoimmune diagnostics reagents, kits, and instruments:

• Thermo Fisher Scientific Inc.
• Werfen, S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Revvity, Inc.
• Grifols, S.A.
• Exagen Inc.

Factors Contributing to the Growth of the Autoimmune Diseases Diagnostics Market

Market Drivers

Rising Global Prevalence of Autoimmune Diseases

The rising global prevalence of autoimmune diseases is the foundational driver of autoimmune diagnostics demand. More than 80 autoimmune diseases have been identified, including systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, and autoimmune thyroid disease, and collectively they affect a large and growing share of the population, with higher prevalence among women. The incidence of many autoimmune diseases has been rising, attributed to genetic, environmental, and lifestyle factors, expanding the population requiring diagnosis and monitoring. Each patient typically requires autoantibody and supporting testing for diagnosis and ongoing management, generating sustained and recurring demand. The chronic, lifelong nature of autoimmune disease ensures repeat testing over time. As the prevalence and incidence of autoimmune diseases continue to rise worldwide and diagnosis rates improve, demand for autoimmune diagnostics continues to grow, reinforcing sustained market growth throughout the forecast period.

Growing Awareness and Emphasis on Early Diagnosis

Growing awareness of autoimmune diseases and an emphasis on earlier, more accurate diagnosis are substantial drivers of diagnostics demand. Autoimmune diseases are often difficult to diagnose, with nonspecific symptoms and long diagnostic delays, and increasing awareness among patients, primary care physicians, and specialists is driving earlier testing and referral. Professional societies and patient organizations are promoting recognition and timely diagnosis, and evolving guidelines incorporate autoantibody testing in diagnostic criteria, such as antinuclear antibody and specific autoantibody testing for systemic lupus erythematosus and related conditions. Earlier diagnosis enables timely treatment, better outcomes, and prevention of organ damage, reinforcing the clinical value of testing. Rising health awareness and access to care further increase testing. As awareness grows and health systems emphasize earlier diagnosis of autoimmune disease, testing volumes are expected to be an important driver of market growth across the forecast period.

Market Restraints

Despite steady momentum, the Autoimmune Diseases Diagnostics market faces material constraints. The complexity and diagnostic challenge of autoimmune diseases, with nonspecific and overlapping symptoms and the need for clinical correlation, can limit the interpretability and demand for testing and contribute to long diagnostic pathways. Test standardization and variability remain challenges, particularly for indirect immunofluorescence, which is subjective and operator-dependent, and differences between assays and platforms can complicate result comparison. Reimbursement and cost-containment pressures constrain testing volumes and the adoption of newer, higher-cost multiplex and specialized assays in some settings. A shortage of trained laboratory personnel and specialists in immunology and rheumatology can constrain capacity and interpretation. The high cost of automated instruments and platforms limits adoption among smaller laboratories, and the need for validation, quality control, and accreditation adds operational burden. Rigorous and evolving regulatory requirements for in vitro diagnostic devices, including the European In Vitro Diagnostic Regulation and Food and Drug Administration pathways, add cost and complexity to product development and market entry. Finally, uneven laboratory infrastructure, limited awareness, and affordability constraints in emerging markets can restrict access and adoption across parts of the forecast period.

Autoimmune Diseases Diagnostics Market Segment Analysis

The Autoimmune Diseases Diagnostics Market is segmented by product (reagents and kits, instruments), test type (antinuclear antibody test, autoantibody test, complete blood count, comprehensive metabolic panel, c-reactive protein, erythrocyte sedimentation rate, urinalysis), technology (immunofluorescence assay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, multiplex and line immunoassay, others), disease type (systemic autoimmune disease, localized autoimmune disease), end-user (hospitals and clinics, diagnostic and reference laboratories, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Reagents and Kits.

The reagents and kits segment accounted for 68% of the Autoimmune Diseases Diagnostics market in 2025. Reagents and kits dominate because autoimmune diagnostics is a high-volume, recurring-use field in which every test consumes assay-specific reagents, antibodies, substrates, calibrators, and controls. Antinuclear antibody and specific autoantibody tests, together with supporting tests, are performed continuously across immunofluorescence, enzyme immunoassay, chemiluminescence, and multiplex platforms, generating steady, per-test demand that far exceeds one-time instrument purchases in aggregate revenue. Leading suppliers such as Thermo Fisher through Phadia and EliA, Werfen through Inova Diagnostics, Bio-Rad through BioPlex, and Revvity through EUROIMMUN generate large recurring reagent revenue, underpinning the razor-and-blade model of the industry. The instruments segment, including automated immunofluorescence, chemiluminescence, and multiplex analyzers, represents important capital revenue and anchors reagent pull-through, and drives the shift toward automation. Nonetheless, the continuous, volume-driven consumption of reagents and kits, tied directly to testing volume, secures the segment's leadership across the forecast period.

By Test Type

Dominant Subsegment: Antinuclear Antibody Test.

The antinuclear antibody test segment accounted for 32% of the Autoimmune Diseases Diagnostics market in 2025. The antinuclear antibody test dominates because it is the primary first-line screening test for systemic autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, and Sjogren's syndrome, and is one of the most frequently ordered autoimmune tests. Antinuclear antibody testing, performed by indirect immunofluorescence as the reference method and by enzyme and chemiluminescence immunoassays, is central to diagnostic criteria and initial evaluation, generating high volumes. The broader autoantibody test segment, including specific tests such as double-stranded DNA, extractable nuclear antigens, cyclic citrullinated peptide, and many others, represents a large and growing category used for specific diagnosis, subclassification, and monitoring. Supporting tests, including complete blood count, comprehensive metabolic panel, C-reactive protein, erythrocyte sedimentation rate, and urinalysis, are widely used to assess inflammation, organ involvement, and disease activity. Nonetheless, the role of antinuclear antibody testing as the high-volume first-line screen for systemic autoimmune disease secures its leadership across the forecast period, with specific autoantibody testing growing strongly alongside.

Autoimmune Diseases Diagnostics Market Region Analysis

Dominant Region: North America

North America accounted for 42% of the global Autoimmune Diseases Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of autoimmune diseases, advanced laboratory infrastructure, high awareness and diagnosis rates, and the presence of leading manufacturers. The United States leads on the strength of a large and well-equipped hospital, clinic, and reference laboratory network, high testing volumes, rapid adoption of automated and multiplex testing, and the presence of major players including Thermo Fisher Scientific, Bio-Rad, Werfen through Inova Diagnostics, Abbott, and Exagen. Disease burden is substantial, with a large population affected by autoimmune diseases and rising diagnoses. The regulatory environment is well established, with the Food and Drug Administration providing clearance pathways for in vitro diagnostic devices. Reimbursement supports autoimmune testing, and strong research infrastructure, biomarker discovery, and laboratory investment further reinforce the market. This combination of disease burden, infrastructure, and technology adoption reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Autoimmune Diseases Diagnostics market. The region's elevated CAGR is driven by large populations, a rising burden of autoimmune diseases, expanding healthcare access, and growing laboratory infrastructure across China, India, Japan, South Korea, and Southeast Asia. Rising awareness and diagnosis of autoimmune diseases, together with growing healthcare investment and insurance coverage, are expanding demand for testing, and improving laboratory capacity and centralization are broadening access to autoimmune diagnostics. China and India are expanding domestic diagnostic manufacturing and laboratory networks, and rising incomes and awareness are increasing testing demand. Both multinational and regional manufacturers are expanding their presence and automated and value-tier offerings. Government and private investment in diagnostic capacity further supports growth. The combination of large populations, rising disease burden, expanding access, and growing laboratory infrastructure positions Asia-Pacific as the highest-growth region over the forecast period.

Regional Commentary

North America

North America accounted for 42% of the global Autoimmune Diseases Diagnostics market revenue in 2025. The United States dominates the region on the strength of advanced laboratory infrastructure, high awareness and diagnosis rates, and the presence of leading manufacturers, while Canada contributes through its public laboratory networks and Mexico expands access within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom. Growth is supported by a high autoimmune disease burden, established laboratory networks, and the presence of major manufacturers such as Werfen, Revvity through EUROIMMUN, and Grifols, while the European In Vitro Diagnostic Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by large populations, a rising burden of autoimmune diseases, expanding healthcare access, and growing laboratory infrastructure across China, India, Japan, South Korea, and Southeast Asia. Expanding domestic manufacturing and automated and value-tier offerings are broadening access and adoption.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of autoimmune diseases, improving laboratory capacity, and expanding healthcare access are broadening adoption, while investment in diagnostic infrastructure supports growth.

Autoimmune Diseases Diagnostics Market Competitive Landscape

The Autoimmune Diseases Diagnostics market is classified as Moderately Concentrated. A group of large diagnostics companies holds the majority of revenue through broad reagent, kit, and instrument portfolios, led by Thermo Fisher Scientific, Werfen through Inova Diagnostics, Bio-Rad Laboratories, and Revvity through EUROIMMUN, while Danaher through Beckman Coulter, Siemens Healthineers, Roche, Abbott, Grifols, and Exagen hold significant positions, and a field of specialized and regional players competes across the market. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with revenue concentrated among a few large and specialized autoimmune diagnostics companies alongside broader in vitro diagnostics players and regional competitors.
• Leading players: Thermo Fisher Scientific, Werfen through Inova Diagnostics, Bio-Rad Laboratories, and Revvity through EUROIMMUN anchor the top tier, with Danaher, Siemens Healthineers, Roche, Abbott, Grifols, and Exagen holding significant positions.
• Geographic reach: Leaders operate global commercial, manufacturing, and support networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players hold broad portfolios spanning immunofluorescence, enzyme immunoassay, chemiluminescence, and multiplex platforms and extensive autoantibody menus.
• Pipeline strength: Deep pipelines in automated immunofluorescence, high-throughput chemiluminescence, multiplex testing, novel autoantibody biomarkers, and digital and artificial intelligence-assisted interpretation.
• Strategic partnerships: Collaborations with hospitals, reference laboratories, and research institutions, and biomarker and content partnerships, shape the competitive landscape.
• M&A activity: Consolidation continues, exemplified by PerkinElmer's acquisition of EUROIMMUN, now part of Revvity, and ongoing portfolio expansion.
• Manufacturing capabilities: Large-scale reagent and kit manufacturing and instrument production are key competitive strengths and barriers to entry.
• Innovation focus: Automated and digital immunofluorescence, high-throughput chemiluminescence, multiplex testing, novel autoantibody biomarkers, and precision diagnostics for autoimmune disease.

Autoimmune Diseases Diagnostics Market Recent Developmental Activities

In 2023 and 2024, Werfen expanded its autoimmune portfolio through Inova Diagnostics, including the Aptiva particle-based multi-analyte technology and automated immunofluorescence with NOVA View. Strategic significance: Strengthens Werfen's leadership in autoimmune testing and advances multiplex and automated immunofluorescence.

In 2023 and 2024, Revvity, through EUROIMMUN, expanded its autoimmune assay menu and automated immunofluorescence and processing systems, including EUROPattern pattern recognition. Strategic significance: Reinforces EUROIMMUN's strong position in immunofluorescence and automated autoimmune testing.

Autoimmune Diseases Diagnostics Market Segmentation

Autoimmune Diseases Diagnostics Market by Product

• Reagents and Kits
• Instruments

Autoimmune Diseases Diagnostics Market by Test Type

• Antinuclear Antibody Test
• Autoantibody Test
• Complete Blood Count
• Comprehensive Metabolic Panel
• C-Reactive Protein
• Erythrocyte Sedimentation Rate
• Urinalysis

Autoimmune Diseases Diagnostics Market by Technology

• Immunofluorescence Assay
• Enzyme-Linked Immunosorbent Assay
• Chemiluminescence Immunoassay
• Multiplex and Line Immunoassay
• Others

Autoimmune Diseases Diagnostics Market by Disease Type

• Systemic Autoimmune Disease
• Localized Autoimmune Disease

Autoimmune Diseases Diagnostics Market by End-User

• Hospitals and Clinics
• Diagnostic and Reference Laboratories
• Others

Autoimmune Diseases Diagnostics Market by Geography

• North America Autoimmune Diseases Diagnostics Market
• United States Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Canada Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Mexico Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Europe Autoimmune Diseases Diagnostics Market
• Germany Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• United Kingdom Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• France Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Italy Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Spain Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Rest of Europe Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Asia-Pacific Autoimmune Diseases Diagnostics Market
• China Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Japan Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• India Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Australia Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• South Korea Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Rest of the World (RoW) Autoimmune Diseases Diagnostics Market
• Middle East Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• Africa Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)
• South America Autoimmune Diseases Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Autoimmune Diseases Diagnostics Market Report Study

• Market size analysis for the current autoimmune diseases diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global autoimmune disease diagnostics market.
• Various opportunities available for competitors in the autoimmune diseases diagnostics market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current autoimmune diseases diagnostics market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for autoimmune diseases diagnostics market growth in the future?

Target audience who can benefit from this autoimmune diseases diagnostics market report study

• Autoimmune Diseases Diagnostics product providers
• Research organizations and consulting companies
• Autoimmune Diseases Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in autoimmune diseases diagnostics products
• Various end-users who want to know more about the autoimmune diseases diagnostics market and the latest technological developments in the autoimmune diseases diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Autoimmune Diseases Diagnostics market?

The Autoimmune Diseases Diagnostics market is projected to expand at a CAGR of 5.53% during the forecast period of 2026-2034.

Q2. What is the market size of the Autoimmune Diseases Diagnostics market?

The Autoimmune Diseases Diagnostics market is estimated at USD 4.9 billion in 2025 and is projected to reach USD 8.0 billion by 2034.

Q3. Which region dominates the Autoimmune Diseases Diagnostics market?

North America dominated the Autoimmune Diseases Diagnostics market with a 42% share of global revenue in 2025, supported by a high autoimmune disease burden, advanced laboratory infrastructure, high awareness and diagnosis rates, supportive FDA pathways, and the presence of leading manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Autoimmune Diseases Diagnostics market?

The principal drivers are the rising global prevalence of autoimmune diseases; growing awareness and emphasis on earlier diagnosis; technological advancement in automated immunofluorescence, chemiluminescence, and multiplex testing; and the expanding autoantibody biomarker menu, reinforced by the growing use of diagnostics to guide biologic therapy and expanding healthcare access in emerging markets.

Q5. Who are the major players in the Autoimmune Diseases Diagnostics market?

The major players include Thermo Fisher Scientific Inc., Werfen, S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Revvity, Inc., Grifols, S.A., and Exagen Inc., among other active manufacturers profiled in the Competitive Landscape section. Thermo Fisher, Werfen through Inova Diagnostics, Bio-Rad, and Revvity through EUROIMMUN hold leading positions in autoimmune testing.